Pure Global
NCT06344533

Study of JMKX003142 Injection in Chinese Healthy Subjects

Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy Adult Subjects
Jemincare·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Adult
Drug/Device/Intervention
JMKX003142 Injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jemincare
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Apr 10, 2024
End date
May 30, 2025
Enrollment
78 participants
Primary outcome

Number of the Adverse Events that are related to the single dose treatment,Number of the Adverse Events that are related to the multiple dose treatment

Summary

To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142
 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and
 Multiple-ascending Doses in Chinese Healthy Adult Subjects

ICD-10 classifications
Healthy person accompanying sick personObesity, unspecifiedLifestyle-related conditionAdult-onset Still diseaseObesity
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06344533
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06344533 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jemincare and is currently Not yet recruiting. The study focuses on Healthy Adult. Target enrollment is 78 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.